Timing of first recurrence of syncope predicts syncopal frequency after a positive tilt table test result

Cardiovascular Research Group, University of Calgary, Alberta, Canada.

OBJECTIVES: This study sought to determine whether the time to first recurrence of syncope after a positive isoproteremol-tilt table test result accurately predicts the eventual frequency of syncope. BACKGROUND: Both patient care and future clinical trials involving patients with neuromediated syncope will require a simple measure that reflects the frequency of syncope. The time from tilt table testing to the first recurrence of syncope might be such a measure. METHODS: A cohort of 46 patients with syncope, in a university outpatient clinic, who had at least one syncopal spell after a positive isoproterenol-tilt table test result were followed up for up to 6.5 years (mean [+/-SD] 48 +/- 14 months). The time from tilt table testing to the first recurrence of syncope was correlated. RESULTS: A total of 40 of 46 patients had more than one recurrent spell, with a median of eight recurrent spells. The time to the first syncopal spell predicted the frequency of spells with r = -0.79 (p < 0.001), whereas the time to the second spell predicted the frequency with r = -0.92 (p < 0.001). Patients who fainted within 1 month of tilt testing had a geometric mean frequency of 1.35 spells/month (95% confidence limits 0.49, 3.74) compared with patients who fainted 1 to 24 months after testing (0.12 spells/months; 95% confidence limits 0.07 to 0.18, p < 0.001). Finally, the frequency of syncopal spells bore no relation to the duration of follow-up. CONCLUSIONS: The time to the first recurrent spell predicts the frequency of syncopal spells after a positive tilt table test result, and the instantaneous risk of syncope is constant.

This article has been cited by other articles:

				R. Sheldon, S. Connolly, S. Rose, T. Klingenheben, A. Krahn, C. Morillo, M. Talajic, T. Ku, F. Fouad-Tarazi, D. Ritchie, et al. Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope Circulation, March 7, 2006; 113(9): 1164 - 1170. [Abstract] [Full Text] [PDF]

				A. Raviele, F. Giada, C. Menozzi, G. Speca, S. Orazi, G. Gasparini, R. Sutton, M. Brignole, and for the Vasovagal Syncope and Pacing Trial Investi A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE) Eur. Heart J., October 1, 2004; 25(19): 1741 - 1748. [Abstract] [Full Text] [PDF]

				R. Sheldon, S. Rose, S. Connolly, and on behalf of the POST investigators Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope: Rationale and study design Europace, January 1, 2003; 5(1): 71 - 75. [Abstract] [PDF]

				R. S. Sheldon, S. R. Raj, S. Rose, and S. J. Connolly Beta-blockers in syncope: the jury is still out J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2135 - 2135. [Full Text] [PDF]

				F. Ammirati, F. Colivicchi, and M. Santini Permanent Cardiac Pacing Versus Medical Treatment for the Prevention of Recurrent Vasovagal Syncope : A Multicenter, Randomized, Controlled Trial Circulation, July 3, 2001; 104(1): 52 - 57. [Abstract] [Full Text] [PDF]

				R. Sheldon and S. Rose Components of clinical trials for vasovagal syncope Europace, January 1, 2001; 3(3): 233 - 240. [Abstract] [PDF]

				S. J. Connolly, R. Sheldon, R. S. Roberts, M. Gent, and on Behalf of the Vasovagal Pacemaker Study Investi The North American vasovagal pacemaker study (VPS) : A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope J. Am. Coll. Cardiol., January 1, 1999; 33(1): 16 - 20. [Abstract] [Full Text] [PDF]